Ferric carboxymaltose: a highly effective and safe treatment of iron deficiency

Česká verzia

Authors: M. Bortlík
Authors place of work: Klinické a výzkumné centrum pro střevní záněty ISCARE I. V. F. a. s. a Interní klinika 1. LF UK a ÚVN, Praha
Published in the journal: Gastroent Hepatol 2014; 68(1): 85-87
Category: Drug Profile

Zdroje

1. Hrdlička L, Kohout P, Liberda M et al. Doporučený postup pro diagnostiku a léčbu anémie u IBD. Gastroent Hepatol 2012; 66(4): 280–285.

2. Cada DJ, Levien TL, Baker DE. Ferric carboxymaltose. Hosp Pharm 2014; 49(1): 52–59. doi: 10.1310/hpj4901-52.

3. Beshara S, Sörensen J, Lubberink M et al. Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol 2003; 120(5): 853–859.

4. Bátovský M. Súčasný prístup k anémii u pacientov s nešpecifickými črevnými zápalmi. Gastreont Hepatol 2012; 66(2): 131–135.

5. SÚKL. Ferinject: Souhrn údajů o přípravku. Dostupné z: http://www.sukl.cz/modules/me-dication/detail.php?code=0155379&tab=texts.

6. Kulnigg S, Stoinov S, Simanenkov V et al. A novel intravenous iron formulation for treatment of anémia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008; 103(5): 1182–1192. doi: 10.1111/j.1572-0241.2007.01744.x.

7. Evstatiev R, Marteau P, Iqbal T et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anémia in inflammatory bowel disease. Gastroenterology 2011; 141(3): 846–853. doi: 10.1053/j.gastro.2011.06.005.

8. Reinisch W, Chowers Y, Danese S et al. The management of iron deficiency in inflammatory bowel disease – an online tool developed by the RAND/UCLA appropriateness method. Aliment Pharmacol Ther 2013; 38(9): 1109–1118. doi: 10.1111/apt.12493.